From: NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia
Variables | Univariate analysis (Kaplan-Meier) | Multivariate analysis | |
---|---|---|---|
P-value | HR(95%CI) | P-value | |
TTT | |||
 Age >60 y | 0.842 | 0.83 (0.46–1.49) | 0.530 |
 Sex (male) | 0.821 | 1.52 (0.85–2.71) | 0.159 |
 Binet B/C stage | <0.001 | 2.48 (1.27–4.84) | 0.008 |
 ALC ≥50×109/L | 0.977 | 0.90 (0.50–1.63) | 0.721 |
 LDH>ULN | 0.767 | 0.72 (0.36–1.43) | 0.348 |
 β2-MG>ULN | 0.095 | 1.49 (0.81–2.74) | 0.204 |
 CD38 (≥30%) | 0.164 | 1.01 (0.55–1.84) | 0.988 |
 ZAP-70 (≥20%) | 0.308 | 0.89 (0.50–1.59) | 0.692 |
 IGHV unmutated | <0.001 | 1.68 (0.97–2.92) | 0.067 |
 p53 aberration | <0.001 | 2.46 (1.19–5.09) | 0.015 |
 NDRG2 expression (high) | 0.001 | 2.01 (1.11–3.64) | 0.022 |
OS | |||
 Age >60 y | 0.700 | 0.89 (0.34–2.35) | 0.814 |
 Sex (male) | 0.633 | 1.33 (0.51–3.48) | 0.563 |
 Binet B/C stage | 0.028 | 0.85 (0.22–3.33) | 0.814 |
 ALC ≥50×109/L | 0.524 | 0.70 (0.22–2.25) | 0.549 |
 LDH>ULN | 0.071 | 1.81 (0.52–6.26) | 0.349 |
 β2-MG>ULN | 0.813 | 1.29 (0.46–3.59) | 0.628 |
 CD38 (≥30%) | 0.002 | 2.01 (0.79–5.13) | 0.143 |
 ZAP-70 (≥20%) | 0.079 | 1.31 (0.44–3.89) | 0.632 |
 IGHV unmutated | <0.001 | 3.03 (1.16–7.95) | 0.024 |
 p53 aberration | <0.001 | 3.95 (1.34–11.67) | 0.013 |
 NDRG2 expression (high) | <0.001 | 3.43 (1.06–11.14) | 0.040 |